Short answer: Tirzepatide (brand names Mounjaro for diabetes and Zepbound for obesity) is one of the fastest-growing GLP-1/GIP drugs and sits among the top players in its class, but the largest absolute market volume in the GLP-1 space is still driven by semaglutide products (Ozempic for diabetes and Wegovy for obesity). Tirzepatide has captured very large sales and prescriptions quickly, and its share is growing, especially in obesity since Zepbound launched, but exact rankings depend on the metric (revenue, prescriptions, or patient counts) and the time period.
Clarifications and what to compare
- Market metric: revenue (sales dollars), prescription volume (units), or patient count?
- Geography: global vs. by region (US, Europe, etc.)?
- Timeframe: trailing 12 months, full year 2023, 2024 YTD, etc.?
What to know in practice
- For diabetes treatment (Mounjaro): Tirzepatide has become a leading GLP-1/GIP therapy in terms of growth and revenue, rapidly climbing toward the top tier of GLP-1 drugs. It competes directly with Ozempic (semaglutide) and other GLP-1s like dulaglutide, liraglutide, etc.
- For obesity treatment (Zepbound): Tirzepatide has surged since its obesity indication launched, making it one of the fastest-growing obesity medicines and closing the gap with Wegovy (semaglutide). Wegovy generally remains the larger revenue driver in the obesity space, but Zepbound is a major competitor with strong uptake.
- Overall class dynamics: The GLP-1 market is led by semaglutide products (largest revenues), with tirzepatide increasingly contributing a substantial share. The gap in absolute market size between tirzepatide and the leading semaglutide products varies by quarter and region.
Would you like a current, numbers-focused snapshot (by revenue, prescriptions, and market share) for Mounjaro and Zepbound vs Ozempic/Wegovy? If yes, tell me:
- which metric you want (revenue, prescriptions, or patients)
- which period (latest quarter, full year 2023, trailing 12 months)
- which region (global or US-focused)
I can pull and summarize the latest figures and cite the sources.